Pluristem Therapeutics Stock News

Check these three penny stocks out for your January watchlist The post Best Penny Stocks to Buy Right Now? 3 For Your List in January appeared first on Penny Stocks to Buy, Picks, News and Information

Pluristem Therapeutics Inc (NASDAQ: PSTI ) and Tnuva Group have collaborated to develop, manufacture and commercialize cultured cell-based products for the food industry. Tnuva Group is the largest food producer in Israel and the Israeli player in the field of alternative dairy and protein products. The collaboration started with the incorporation of a new company (NewCo) that will receive exclusive, global, royalty-bearing licensing rights to use Pluristem''s Full story available on Benzinga.com

Check these three penny stocks out for your January watchlist The post Best Penny Stocks to Buy Right Now? 3 For Your List in January appeared first on Penny Stocks to Buy, Picks, News and Information

Pluristem Therapeutics (PSTI) and Tnuva Group, Israel’s largest food producer, announce the launch of an innovative collaboration to develop, manufacture and commercialize…

HAIFA, Israel, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI) (“Pluristem” or “the Company”), a leading biotechnology company, and Tnuva Group (“

Pluristem Therapeutics Inc (NASDAQ: PSTI) and Tnuva Group have collaborated to develop, manufacture and commercialize cultured cell-based products for the food industry.  Tnuva Group is the larges

Pluristem Therapeutics Inc (PSTI) shares closed 3.3% lower than its previous 52 week low, giving the company a market cap of $49M. The stock is currently down 78.1% year-to-date, down 78.3% over the past 12 months, and down 89.3% over the past five years. This week, the Dow Jones Industrial Average rose 2.6%, and the S&P 500 rose 3.0%. Trading Activity Trading volume this week was 61.6% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.5. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 323.1% The company's stock price performance over the past 12 months lags the peer average by 296.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Kiniksa (KNSA) reports that the phase III portion of mavrilimumab???s phase II/III study for COVID-related ARDS did not meet the primary efficacy endpoint.

Pluristem's (PSTI) phase II studies evaluating PLX-PAD cells for treating acute respiratory distress syndrome associated with COVID-19 fail to achieve the primary endpoint.

Pluristem's (PSTI) phase II studies evaluating PLX-PAD cells for treating acute respiratory distress syndrome associated with COVID-19 fail to achieve the primary endpoint.

HAIFA, Israel, Dec. 27, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) (the “Company”), a leading biotechnology company, today announced topline results from its

Pluristem Therapeutics (NASDAQ:PSTI) and Outlook Therapeutics (NASDAQ:OTLK) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation and institutional ownership. Profitability This table compares Pluristem Therapeutics and Outlook Therapeutics’ net margins, return on equity and […]

Wall Street analysts expect that Pluristem Therapeutics Inc. (NASDAQ:PSTI) will post earnings per share of ($0.41) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Pluristem Therapeutics earnings. Pluristem Therapeutics posted earnings per share of ($0.49) in the same quarter last year, which indicates a positive year over []

Zacks Investment Research lowered shares of Pluristem Therapeutics (NASDAQ:PSTI) from a buy rating to a hold rating in a research report released on Tuesday morning, Zacks.com reports. According to Zacks, PLURISTEM THERAPEUTICS INC. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic [] The post Pluristem Therapeutics (NASDAQ:PSTI) Stock Rating Lowered by Zacks Investment Research appeared first on ETF Daily News .

Humacyte (NASDAQ:HUMA) and Pluristem Therapeutics (NASDAQ:PSTI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, risk, dividends, analyst recommendations and institutional ownership. Profitability This table compares Humacyte and Pluristem Therapeutics net margins, return on equity and return on [] The post Financial Survey: Humacyte (NASDAQ:HUMA) versus Pluristem Therapeutics (NASDAQ:PSTI) appeared first on ETF Daily News .